WO1994027671A1 - Electrotransport agent delivery device - Google Patents
Electrotransport agent delivery device Download PDFInfo
- Publication number
- WO1994027671A1 WO1994027671A1 PCT/US1994/006070 US9406070W WO9427671A1 WO 1994027671 A1 WO1994027671 A1 WO 1994027671A1 US 9406070 W US9406070 W US 9406070W WO 9427671 A1 WO9427671 A1 WO 9427671A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liner
- components
- mating
- component
- electrotransport
- Prior art date
Links
- 230000001070 adhesive effect Effects 0.000 claims abstract description 57
- 230000013011 mating Effects 0.000 claims abstract description 57
- 239000000853 adhesive Substances 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 238000000576 coating method Methods 0.000 claims description 20
- 239000011248 coating agent Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 230000002093 peripheral effect Effects 0.000 claims description 9
- 230000001464 adherent effect Effects 0.000 claims description 6
- 238000012377 drug delivery Methods 0.000 abstract description 4
- -1 poly(styrenebutadiene) Polymers 0.000 description 23
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 229920001477 hydrophilic polymer Polymers 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000007373 indentation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920001600 hydrophobic polymer Polymers 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002367 Polyisobutene Polymers 0.000 description 5
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 3
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 3
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- 239000011231 conductive filler Substances 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960003726 vasopressin Drugs 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- IWTBVKIGCDZRPL-UHFFFAOYSA-N 3-methylpentanol Chemical compound CCC(C)CCO IWTBVKIGCDZRPL-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102100022831 Somatoliberin Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000009864 tensile test Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- TZYRSLHNPKPEFV-UHFFFAOYSA-N 2-ethyl-1-butanol Chemical compound CCC(CC)CO TZYRSLHNPKPEFV-UHFFFAOYSA-N 0.000 description 1
- PFNHSEQQEPMLNI-UHFFFAOYSA-N 2-methyl-1-pentanol Chemical compound CCCC(C)CO PFNHSEQQEPMLNI-UHFFFAOYSA-N 0.000 description 1
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- BWDBEAQIHAEVLV-UHFFFAOYSA-N 6-methylheptan-1-ol Chemical compound CC(C)CCCCCO BWDBEAQIHAEVLV-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 239000004821 Contact adhesive Substances 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 108010057021 Menotropins Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 229920000459 Nitrile rubber Polymers 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010047196 Urofollitropin Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 229940116211 Vasopressin antagonist Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 108010060162 alglucerase Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000003152 bradykinin antagonist Substances 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- NTXGQCSETZTARF-UHFFFAOYSA-N buta-1,3-diene;prop-2-enenitrile Chemical compound C=CC=C.C=CC#N NTXGQCSETZTARF-UHFFFAOYSA-N 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 229960002976 chymopapain Drugs 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960002845 desmopressin acetate Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HDERJYVLTPVNRI-UHFFFAOYSA-N ethene;ethenyl acetate Chemical class C=C.CC(=O)OC=C HDERJYVLTPVNRI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- XFHJDMUEHUHAJW-UHFFFAOYSA-N n-tert-butylprop-2-enamide Chemical compound CC(C)(C)NC(=O)C=C XFHJDMUEHUHAJW-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229950011188 pentigetide Drugs 0.000 description 1
- KQDIGHIVUUADBZ-PEDHHIEDSA-N pentigetide Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O KQDIGHIVUUADBZ-PEDHHIEDSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 229950003551 ramoplanin Drugs 0.000 description 1
- 108010076689 ramoplanin Proteins 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000000807 solvent casting Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960004371 urofollitropin Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003038 vasopressin antagonist Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/0436—Material of the electrode
Definitions
- This invention relates to electrotransport agent delivery devices, and more particularly, to such devices having reusable and disposable parts.
- Electrotransport refers generally to the passage of a substance through a substrate, such as skin, mucous membrane, or nails, induced by application of an electrical potential.
- a beneficial therapeutic agent may be introduced into the human body by electrotransport.
- electrotransport One type of electrotransport, electroosmosis, involves the movement of a liquid out of or through a synthetic or biological membrane under the influence of an electric field.
- a more widely used electrotransport process, iontophoresis involves the electrically induced transport of charged ions.
- electroporation involves the transport of an agent through transiently-existing pores formed in the substrate under the influence of an electric field. However, in any given electrotransport process, more than one of these processes may be occurring simultaneously to a certain extent.
- electrotransport should be given its broadest possible interpretation so that it includes the electrically induced or enhanced transport of at least one agent, which may be charged, uncharged, or mixtures thereof, regardless of the specific mechanism or mechanisms by which the agent actually is transported.
- Electrotransport devices generally use at least two electrodes which are in electrical contact with some portion of the skin, nails, mucous membrane, or other surface of the body.
- One electrode commonly referred to as the "donor” or “active” electrode, is the electrode from which the agent is delivered into the body.
- the other electrode typically termed the “counter” or “return” electrode, serves to close the electrical circuit through the body.
- an agent to be delivered is positively charged, ie, a cation, then the anode will be the active or donor electrode, while the cathode serves to complete the circuit.
- an agent is negatively charged, ie, an anion
- the cathode will be the donor electrode.
- both the anode and cathode may be considered donor electrodes if both anionic and cationic agent ions are to be delivered.
- electrotransport delivery devices generally require at least one reservoir or source of the agent to be delivered to the body.
- donor reservoirs include a pouch or cavity as described in Jacobsen, US Pat. No. 4,250,878, a porous sponge or pad as disclosed in Jacobsen et al, US Pat. No. 4,141,359, and a pre-formed gel body as described in Webster, US Pat. No. 4,383,529, which are herein incorporated by reference.
- Such donor reservoirs are electrically connected to, and positioned between, the anode or cathode and the body surface, to provide a fixed or renewable source of one or more agents or drugs.
- electrotransport delivery devices have an electrical power source, some having an electrical controller designed to regulate the rate of drug delivery.
- Other optional elements include rate-controlling membranes, insulating members, and protective backing members.
- electrotransport devices may be designed to be distributed in two general components, one being a disposable component and the other being a reusable component.
- the drug or other beneficial agent contained in the donor reservoir may be depleted long before the completion of the useful life of certain hardware used in the device such as the power source or electrical controller.
- the disposable component may contain an agent reservoir and the reusable component may contain an electrical controller component and/or an electrical power source.
- the power source may be a battery having a limited life cycle, while the electrical controller contains long-lasting solid state circuitry.
- the battery may be placed in the disposable component, while the electrical controller is placed in the reusable component.
- a "reusable component” refers to one component of a electrotransport device whose useful life exceeds that of a second component, referred to herein as a "disposable component", wherein the two components may be separated so that the reusable component may subsequently be reused while the disposable component is discarded and replaced with another disposable component.
- the reusable and disposable components are mated to one another, by mechanical and/or electrical connections, in order to form a complete electrotransport device, which device is then adapted to be placed in agent transmitting relation with the body surface (eg, skin or mucosal membrane) of a patient.
- Exemplary of electrotransport delivery devices having reusable and disposable components are those disclosed in US Patent Nos. 4,865,582, 4,950,229 (see column 8, lines 38-40); and 5,037,381.
- US Pat. No. 4,865,582 discloses an electrically powered transdermal drug applicator having a reusable power supply and a disposable drug reservoir.
- the drug reservoir has an adherent surface 13 which presumably has a release liner (similar to liner 48) affixed thereto prior to device assembly.
- the end user peels off the release liner, then applies the adherent surface of the disposable drug reservoir to the reusable power supply/controller 54.
- the release liner is intended to mask or protect the adhesive prior to assembly of the device and is removed prior to alignment of the reusable and disposable components. Unfortunately it is sometimes difficult to precisely align the controller 54 with the disposable component during mating of the two components.
- an object of the present invention to provide an electrotransport device having reusable and disposable components adapted to be adhesively mated, the alignment of which can be easily adjusted after the components have been brought in contact with one another.
- a further object of this invention to provide for the mechanical and electrical connection of the reusable and disposable components of an electrotransport device prior to adhesive mating of the components to one another.
- Yet another object of this invention is to provide a method of preventing premature adhesion of two components of an electrotransport device during alignment of the components.
- the electrotransport device of this invention which achieves these objects comprises two components which must be aligned and mated to one another prior to initiation of agent delivery.
- One component is a reusable component, preferably containing a power source and associated control circuitry.
- the other component is a disposable component which preferably includes the beneficial agent to be delivered.
- the disposable and reusable components have surfaces adapted to mate with and adhere to one another in a plurality of mating orientations, at least one of which is the desired mating orientation. At least one of the components has a mating surface having adhesive properties.
- the disposable component has the adhesive mating surface.
- Means are provided for aligning the reusable and disposable components in the desired mating orientation.
- An adhesive release liner is disposed on the adhesive mating surface.
- the liner prevents the mating surfaces from adhering to one another during alignment of the components. Once the components are aligned in the desired mating orientation, the liner is interposed between the mating surfaces. The liner is readily manually removable from this interposed position in order to permit adhesive mating of the components in the desired mating orientation.
- one or more mechanical connectors are provided both for mechanically connecting the components. Most preferably, the mechanical connection also serves to electrically connect the components.
- FIGURE 1 is a perspective view of one embodiment of the electrotransport device after connection of the reusable and disposable components and prior to removal of the removable liner.
- FIGURE 2 is an exploded view of the device of FIG. 1.
- FIGURE 3 is a plan view of the removable liner of FIG. 1 in an unfolded position.
- FIGURE 4 is a plan view of another embodiment of the removable liner of this invention in an unfolded position.
- FIGURE 5 is a perspective view of the removable liner of FIG. 4 in a folded position.
- FIGURE 6 is an exploded perspective view of one embodiment of an electrotransport device of this invention wherein the reusable and disposable components have corresponding indentations permitting exposure of a grasping means on the removable liner.
- FIGURE 7 is a cross sectional view of one embodiment of a disposable section of the present invention.
- FIGURE 8A is a plan view of one component of a two-piece removable liner embodiment in the unfolded position.
- FIGURE 8B is a plan view of the FIG. 8A component in a folded position.
- FIGURE 9A is a plan view of a second component of a two-piece removable liner embodiment in the unfolded position.
- FIGURE 9B is a plan view of the FIG. 9A component in a folded position.
- FIGURE 10 is a plan view of the assembled two-piece removable liner assembly incorporating FIGS. 7B and 8B liners.
- FIGURE 11 is an exploded perspective view of one embodiment of the electrotransport device having the two-piece removable liner of FIG. 10.
- FIGS. 1 and 2 illustrate one embodiment of an electrotransport device 1 of this invention.
- Device 1 comprises a reusable component 2, a disposable component 4 and a removable liner 8 disposed therebetween.
- Reusable component 2 preferably contains the electric power source and related control circuitry, while disposable component 4 preferably contains donor and counter electrodes and reservoirs, as shown more clearly in FIG. 6.
- the mating surface of one of the components, preferably the disposable component is adhesive so that the two components can be releasably bonded together after removal of the liner, as described in detail below. Further, the adhesive surface allows liner 8 to be releasably affixed on the disposable component during shipment of the component and assembly of the device.
- Fig. 1 shows components 2 and 4 in their desired mating orientation.
- Device 1 is provided with a means for aligning the components 2 and 4 in the desired mating orientation.
- the means for aligning components 2 and 4 are, in device 1, snap connectors.
- other conventional forms of alignment means may be used in place of snap connectors 6.
- the device is assembled by connecting the reusable component 2 and disposable component 4, to which liner 8 is releasably engaged, by joining male snap connectors 6 on component 4 to female snap connectors (not shown) on the underside of component 2.
- Access means 7 are provided in liner 8 to permit: (a) the male snap connectors 6 to be snapped into their female counterparts with the liner 8 interposed between the components 2 and 4; and (b) the liner 8 to be removed without disturbing the snap connectors 6.
- the aligning means also provides an initial mechanical connection and an electrical connection of the components 2 and 4.
- Snap connections 6 provide at least the additional function of mechanically connecting components 2 and 4, and in cases where the snap connectors 6 are composed of an electrically conductive material (eg, metal or metal coated snap connectors), they provide both additional functions.
- the liner 8 comprises a sheet of material folded over on itself at fold axis 8c to provide a first sheet portion 8a releasably adhered to the adherent mating surface 11 of component 4 and a second sheet portion 8b adjacent to component 2.
- the sheet should have a relatively low coefficient of friction to permit it to slide easily when pulled in the direction of the arrow in FIG. 2 by means of grasping means 10 on one of the ends of liner 8 opposite fold axis 8c.
- Access means in this embodiment are essentially parallel slots in the liner 8 which traverse fold axis 8c and are aligned with snap connectors 6 so that liner 8 does not interfere with the operation of snap connectors 6.
- the sheet portion 8b having grasping means 10 does not contact the component having the adhesive mating surface (ie, surface 11). In this manner, sheet portion 8b slides along a non-adhesive mating surface, as opposed to encountering substantially greater resistance by sliding along an adhesive mating surface.
- orienting liner 8 such that grasping means 10 is not adjacent the adhesive surface 11 minimizes the force required to extract liner 8 after alignment and initial connection of the components 2 and 4. Such an orientation benefits the patient or assembler of the device by reducing the difficulty of assembly.
- Snap connectors 6 align and mechanically connect the components 2 and 4 of the device in their desired mating orientation alignment, as shown in FIG. 1.
- liner 8 is removed by pulling on grasping means 10 in the direction of the arrow. This causes first surface 8a to unroll or peel from the adhesive mating surface 11 of component 4 by means of a tensile force acting essentially normal to surface 11 at the fold axis 8c, both initially and as the fold traverses the surface 11 of component 4.
- the force required to remove liner 8 is significantly less than the shear force, acting parallel to the adhesive surface 11 , that would be required to overcome the bond connecting liner 8 to component 4 over their entire contacting surfaces if liner 8 was in the form of a single sheet and was pulled in the direction of the arrow.
- the slots 7 are located such that fold axis 8c in the liner 8 is not impeded, by interaction with snap connectors 6, from traversing easily across the surfaces of components 2 and 4 as the liner 8 is pulled in the direction of the arrow in FIG. 2.
- FIGS. 2-5 illustrate two preferred embodiments according to the present invention. Both FIGS. 3 and 4 depict a plan view of a removable liner in an extended position, while FIGS. 2 and 5 illustrate corresponding folded positions of the same two liners, respectively.
- FIGS. 2 and 3 show an embodiment wherein a removable liner 8 has two elongated slots 7 therethrough. These elongated slots 7 are provided for mechanical/electrical connectors 6 which extend from disposable component 4 to reusable component 2 when the electrotransport device is assembled (See FIG. 1 for assembly). This design permits the liner to be pulled past the joined snap connectors 6 after alignment of components 2 and 4 is achieved.
- FIGS. 4 and 5 depict another embodiment wherein a removable liner 38 has four circular holes 9 therethrough. Holes directly opposite each other, separated by the fold axis 5, have perforations 3 extending between them.
- perforations refer both (1) to a continuous cut through the liner and (2) to alternating cut and un-cut portions through the liner.
- the perforations 3 aid in preventing tearing of liner 38 during removal thereof from a position interposed between the aligned reusable and disposable components of the electrotransport device.
- An advantage of this embodiment, as with the elongated slot design of FIG. 2 and 3, is that the liner 38 may be easily pulled past the snap connectors 6 after alignment of components 2 and 4.
- the liner 8 may be removed in order to effectively mate components 2 and 4.
- the removable liner 8 is removed by manually grasping and pulling the portion of the liner extending beyond the edges of the disposable and reusable components, on the side opposite the liner perforations or cuts.
- This extended liner portion is herein termed a grasping means 10, as shown in FIG. 2.
- the grasping means 10 preferably extends an adequate distance beyond both components 2 and 4 such that grasping with the user's fingers may be comfortably achievable.
- the grasping means 10 extends from about 6 mm to about 76 mm beyond the peripheral edge of aligned components 2 and 4. More preferably, the tab 10 extends from about 10 mm to about 25 mm beyond component 2 and 4.
- the adhesive coating preferably only on disposable component 4 provides a further means of mechanically securing the components to one another.
- both the reusable component 2 has an indentation 42 and the disposable component 4 has an indentation 44 in their peripheral edge which aligns with the edge of liner 8 which is opposite the fold axis 8c.
- the indentations are located such that they are substantially aligned when the device is assembled. These indentations provide manual access to an exposed portion of the liner 8, ie, another form of a grasping means 10. This alignment of indentations enables the user to more readily grasp the liner for removal purposes.
- the electrotransport device may be designed such that only one of the components 2 or 4 has an indentation exposing a portion of liner 8. The salient feature of this embodiment is that the liner 8 have a sufficient portion exposed so as to allow grasping of the liner for removal purposes.
- FIGURE 7 is a cross sectional view of one embodiment of a disposable component 4.
- the snap connectors 6 are composed of an electrically conductive material, and hence connectors 6 serve not only as the means for aligning the disposable component 4 in the desired mating orientation but also serve to (i) initially (ie, just prior to mating) mechanically connect the disposable component 4 to the reusable component 2; and (ii) electrically connect the electrodes 12 and 14 and the reservoirs 16 and 18 to the source of electrical power (eg, one or more batteries) in the reusable component 2.
- Male portions of snap connectors 6 conduct current from the power source (not shown) to donor and counter electrodes 12 and 14, respectively.
- the donor and counter electrodes 12 and 14 are electrically connected to donor and counter reservoirs 16 and 18, respectively.
- the donor electrode 12 and donor reservoir 16 are insulated from the counter electrode 14 and counter reservoir 18 by insulation 20 disposed therebetween.
- the electrodes and reservoirs are further insulated from the surroundings by peripheral insulation 21.
- Rate controlling membranes 30 and 32 such as disclosed in US Patent No. 5,080,646, can optionally be used to control the flux of donor and counter agents from the reservoirs 16 and 18.
- Adhesive surface 26 is provided for releasably affixing the disposable component 4 to the reusable component 2 as shown in FIG. 2.
- Removable liner 8 of the present invention is positioned on adhesive surface 26, thereby covering substantially all of the adhesive surface 26.
- Peripheral adhesive coating 28 on the skin contacting side of component 4 provides means by which the disposable component may be affixed to a body surface.
- Suitable self-adhering materials include, without limitation, poly(styrenebutadiene) and poly(styrene-isoprene-styrene) block copolymers, and polyisobutylene copolymers.
- Other suitable self-adhering matrix materials are set forth in the art such as are described in US Patent Nos. 4,391 ,278, 4,474,570, and 4,702,732, all of which are incorporated herein by reference.
- a second release liner 15 is preferably positioned adjacent adhesive surface 28, in order to isolate the adhesive coating 28 during shipping and handling of disposable component 4.
- FIGURES 8-10 illustrate another embodiment of the present invention wherein two folded removable liners form a removable liner assembly 70.
- Unfolded liners 50 and 60 are shown in FIGS. 8A and 9A, respectively.
- liners 50 and 60 Prior to use, liners 50 and 60 are folded at a fold axes 54 and 64, respectively, as shown in FIGS. 8B and 9B.
- the folded liners are assembled into the removable liner assembly 70, as shown in FIG. 10, which is configured such that access openings 72 are formed through which the alignment means, and optionally mechanical and/or electrical connectors, on the disposable and/or reusable components may pass.
- Grasping means 52 and 62 are preferably positioned opposite each other in the assembled 2-piece removable liner 70, as shown in FIG. 10.
- FIGURE 11 is an exploded perspective view of an embodiment of the electrotransport device of this invention having the two-piece removable liner assembly of FIG. 10.
- the device is assembled by first aligning removable liners 50 and 60 such that access openings 72 provide sufficient space for passing the male portions of the snap connectors 6 on the disposable component 4 therethrough for affixation to mating aligning and connecting means (not shown) on the underside of reusable component 2.
- aligning and connecting means have established alignment and initial mechanical connection of the components, the two removable liners 50 and 60 may be extracted by pulling grasping means 52 in the direction of the upper arrow, and then pulling grasping means 62 in the direction of the lower arrow.
- disposable component 4 is provided an adhesive mating surface 11 and the removable liners 50 and 60 affixed thereto.
- a skin contact adhesive is preferably also provided on the skin contacting surface of disposable component 4, which adhesive is also preferably protected by a removable liner (not shown in FIG. 11).
- the removable liner is preferably coated on at least one surface with a release coating, which allows only weak adhesive forces between the liner and the adhesive coating.
- a release coating may be used, including without limitation, polymer coatings, waxes, and silicones.
- release coating compositions and methods of applying release coatings which are useful with pressure-sensitive adhesives are disclosed in Handbook of Pressure-Sensitive Adhesive Technology. D. Satas, pp. 370-403 (Van Nostrand Reinhold Co., 1982), which is hereby incorporated by reference.
- the liner is coated with fluorocarbon diacrylate or a polymeric organic silicon material, more commonly referred to as a silicone. Silicones are preferred because silicones are commonly used, relatively inexpensive, and stable in most applications.
- both surfaces of the removable liner or liners may be coated with a release coating, this is not a requirement of the present invention. However, if the removable liner(s) have a release coating on only one side, the liner(s) are preferably folded such that the release coating surface is facing outward, ie, towards the reusable and disposable components. If the liners are coated on only the outer surface, the preferred removal process of liner assembly 70 in FIG. 10 involves first the removal of liner 50 by pulling grasping means 52. Subsequently, tab 62 may be pulled in order to remove liner 60. This sequence of liner removal minimizes the potential for the sticking of the non-coated liner surfaces to the adhesive during the removal process.
- One method of measuring the adhesion between the liner and adhesive coating involves first cutting liner/adhesive sample strips about 2 cm wide, and at least 4 inches long. Then, the liner and adhesive are manually separated at one end of the sample. The separated edge of the liner is attached to a stationary jaw of a tensile testing apparatus, such as a model 1122 tensile tester, available from Instron Corp., Canton, MA. The separated edge of the adhesive is placed in an opposing movable jaw of the tensile testing apparatus. Force is applied to the movable jaw by moving the movable jaw at a nearly constant rate, eg, 1000 mm/min. in a direction opposite the stationary jaw.
- a tensile testing apparatus such as a model 1122 tensile tester, available from Instron Corp., Canton, MA.
- Force is applied to the movable jaw by moving the movable jaw at a nearly constant rate, eg, 1000 mm/min. in a direction opposite the stationary jaw
- the adhesion is typically measured as the force required to separate the liner from the adhesive and is recorded in terms of grams and normalized by dividing by sample width.
- the adhesion between the liner and the adhesive material may range from about 5 to about 100 g/cm of liner width. More preferably, the adhesion between liner and adhesive is about 5 to about 50 g/cm of liner width. The most preferred range of adhesion to liner is about 5 to about 10 g/cm of liner width.
- Adhesives suitable for affixing the reusable component 2 to the disposable component 4 of the present invention include, without limitation, pressure sensitive adhesives such as polyacrylates, polyvinyl ethers, silicones, natural rubber, styrene-butadiene copolymers, styrene-isoprene copolymers, butyl rubber blended with polyisobutylene, butadiene- acrylonitrile rubbers, polychloroprene latex, polyurethanes, poly(vinyl pyrrolidone)s, vinyl pyrrolidone copolymers, ethylene vinyl acetates, and mixtures thereof.
- pressure sensitive adhesives such as polyacrylates, polyvinyl ethers, silicones, natural rubber, styrene-butadiene copolymers, styrene-isoprene copolymers, butyl rubber blended with polyisobutylene, butadiene- acrylonitrile rubbers, polych
- a more complete discussion of pressure-sensitive adhesives appears in Handbook of Pressure-Sensitive Adhesive Technology. D. Satas (Van Nostrand Reinhold Company, 1982), which is inco ⁇ orated herein by reference. In addition to moderate adhesive strengths, biocompatibility is a desirable adhesive characteristic.
- a more preferred group of adhesives for securing the components of the electrotransport device to one another includes silicones, polyacrylates, and polyisobutylenes.
- the thickness of the adhesive coating which secures the reusable component to the disposable component depends on a multitude of factors, including adhesive composition, the compositions of the surfaces which the adhesive contacts, desired adhesion and whether both components have an adhesive coating. Generally, the adhesive coating thickness ranges from about 0.025 mm to about 0.1 mm. More preferably, the adhesive coating thickness is about 0.4 mm to about 0.65 mm.
- the removable liner of the present invention may be composed of a variety of materials.
- the liner does not adhere strongly to the adhesive surface of either the disposable component and/or reusable component.
- a strong adhesion between the liner and the adhesive will cause the patient or user to experience difficulty in manually removing the liner.
- some adhesion between the liner and either disposable component or reusable component is required to hold the liner in place during manufacture, packaging, shipping and during the initial alignment step of the device assembly process.
- Suitable liner materials include, without limitation, polyesters, polyethylenes, poly(vinyl chloride)s, polypropylenes, polystyrenes, polyacrylonitriles, paper, cloth or fabric, and the like and combinations thereof. Some polymer materials, such as polyethylenes, may benefit from addition of mesh or scrim to add strength. Polyesters are more preferable liner materials, while the most preferred polyester is poly(ethylene terephthalate). Poly(ethylene terephthalate) is available commercially from 3M Corporation, Minneapolis, Minnesota.
- the thickness of the liner should be minimized while maintaining sufficient strength to prevent tearing upon removal.
- the required liner thickness is dependent upon the strength of the liner material and the adhesive force between the liner and the adhesive on disposable component and/or reusable component.
- the liner thickness preferably ranges from about 0.01 mm to about 0.25 mm. More preferably, the liner thickness is from about 0.025 mm to about 0.1 mm. Most preferably, the liner thickness ranges from about 0.06 mm to about 0.09 mm.
- the shape and dimensions of the removable liner are a function of the shape and dimensions of the component, or larger of the components, which have an adhesive coating thereon which faces the other component.
- components 2 and 4 have the same general size and shape.
- the removable liner is preferably sized to generally conform to the shape and size of the disposable and reusable components, with the exception of the grasping means as discussed above. However, the removable liner may extend beyond the edges of the components without causing significant problems. While the removable liner is not required to conform exactly to the size and shape of the reusable and disposable components, preferably the liner covers substantially all the adhesive coating or coatings of the components in order to prevent any premature adhesion.
- the electrodes of the present invention are composed of an electrically conductive material such as a metal.
- the electrodes may be formed from metal foil, metal screen, metal deposited or painted on a suitable backing, calendaring, film evaporation, or by embedding a metal powder in a binder matrix.
- suitable metals include silver, zinc, silver chloride, aluminum, platinum, stainless steel, gold, and titanium.
- the anodic electrode may be composed of silver
- the cathodic electrode may be composed of silver chloride.
- the electrodes may be formed of a polymer matrix containing a conductive filler such as a metal powder, powdered graphite, carbon fibers, or other electrically conductive filler material.
- a conductive filler such as a metal powder, powdered graphite, carbon fibers, or other electrically conductive filler material.
- the polymer- based electrodes may be produced by mixing the conductive filler in a polymer matrix, preferably a hydrophobic polymer matrix in order to minimize interaction with any water present in the reservoirs.
- the reusable component contains both a power source and control circuitry.
- the controller may allow manual or automatic feedback adjustment of current fed to the electrodes.
- the invention contemplates those electrotransport systems wherein the reusable component contains a power source without a controlling component. In this system, the agent delivery would be initiated once the agent-transmitting surface of the assembled device was contacted with a body surface.
- the reusable component may contain only control circuitry, while the power source is located in the disposable component. An example of this would be an electrotransport system is powered by entirely by a galvanic couple, wherein power is generated by two dissimilar electrodes.
- the electrodes themselves may generate at least a portion of the electrical power used to deliver the beneficial agent.
- the donor electrode and counter electrode are integral portions of the power generating process.
- Such a galvanic couple powered system activates automatically when body tissue and/or fluids form a complete circuit with the system.
- galvanic couple systems potentially useful in the present invention. Standard electrochemical reactions and the respective reduction potentials are well known in the art. For instance, see the CRC Handbook of Chemistry and Physics, pp. D133-D138, 62 nd edition (1981-1982), which is incorporated herein by reference.
- the electrotransport devices of the present invention use a separate electrical power source, apart from the power generated by way of the electrodes forming a galvanic couple.
- a power source is typically a battery or plurality of batteries, connected in series or in parallel, and positioned electrically between the counter electrode and donor electrode, such that the donor electrode is connected to one pole of the power source and the counter electrode is connected to the opposite pole.
- one or more 3 volt button cell batteries such as PANASONIC*® model CR 2025, are suitable to power electrotransport devices.
- the reusable component may include electronic circuitry for controlling the operation of the electrotransport device.
- the power source may include circuitry designed to permit the patient to manually turn the system on and off, such as with an on-demand medication regime, or to turn the system on and off at some desired periodicity, for example, to match the natural or circadian patterns of the body.
- a relatively simple controller or microprocessor could control the current as a function of time or could generate complex current waveforms such as pulses or sinusoidal waves.
- the control circuitry may also include a biosensor and some type of feedback system which monitors biosignals, provides an assessment of therapy, and adjusts the drug delivery accordingly.
- a typical example is the monitoring of the blood sugar level for controlled administration of insulin.
- the donor reservoir and optional counter reservoir can be any material adapted to abso ⁇ and hold a sufficient quantity of liquid therein in order to permit transport of agent therethrough by iontophoresis.
- gauzes, pads or sponges composed of cotton or other abso ⁇ ent fabric, both natural and synthetic may be used.
- the matrices of the reservoirs are composed, at least in part, of hydrophilic polymer material. Hydrophilic polymer is typically preferred because water is the preferred ion transport medium, and hydrophilic polymers have a relatively high equilibrium water content.
- the matrices of the reservoirs are solid polymer matrices composed, at least in part, of insoluble hydrophilic polymer. Insoluble hydrophilic polymer matrices are sometimes preferred for structural reasons over soluble hydrophilic polymers. However, it should be noted that hydrophobic polymers having a microporous structure sufficient to enable ion transport may be utilized in the agent reservoirs.
- the matrices can be crosslinked with the agent components in place such as a silastic matrix, or the polymers can be prefabricated and so ⁇ ed with the components from solutions as is the case with cellulose, woven fiber pads and sponges.
- the agent reservoirs can alternately be a gel matrix structure, formed similarly to the polymeric matrix structure, wherein the gel is formed of a hydrophilic polymer which is swellable or soluble in water.
- Such polymers can be blended with the components in any ratio, but preferably represent from a few percent up to about 50 percent by weight of the reservoir.
- the polymers can be linear or cross-linked.
- Suitable hydrophilic polymers include copolyesters such as HYTREL (DuPont De Nemours & Co., Wilmington, DE), polyvinylpyrrolidones, poly vinyl alcohol, polyethylene oxides such as POLYOX (Union Carbide Co ⁇ .), CARBOPOL (BF Goodrich of Akron, OH), blends of polyoxyethylene or polyethylene glycols with polyacryiic acid such as POLYOX blended with CARBOPOL, polyacrylamide, KLUCEL, cross-linked dextran such as SEPHADEX (Pharmacia Fine Chemicals, AB, Uppsala, Sweden), WATER LOCK (Grain Processing Co ⁇ ., Muscatine, Iowa) which is a starch-graft-poly(sodium acrylate-co-acrylamide) polymer, cellulose derivatives such as hydroxyethyl cellulose, hydroxypropylmethylcellulose, low-substituted hydroxypropylcellulose, and cross-linked Na- carboxymethyl
- the matrices of the reservoirs 16 and 18 may contain a hydrophobic polymer for enhanced structural rigidity.
- the hydrophobic polymer is heat fusible, in order to improve the lamination of the reservoirs to adjacent components, such as the insulator or a rate controlling membrane.
- Suitable hydrophobic polymers for use in the reservoir matrices include, but are not limited to, polyisobutylenes, polyethylene, polypropylene, polyisoprenes and polyalkenes, rubbers, copolymers such as KRATON, polyvinylacetate, ethylene vinyl acetate copolymers, polyamides such as nylons, polyurethanes, polyvinylchloride, acrylic or methacrylic resins such as polymers of esters of acrylic or methacrylic acid with alcohols such as n-butanol, 1 -methyl pentanol, 2-methyl pentanol, 3-methyl pentanol, 2-ethyl butanol, isooctanol, n-decanol, alone or copolymerized with ethylenically unsaturated monomers such as acrylic acid, methacrylic acid, acrylamide, methacrylamide, N-alkoxymethyl acrylamides, N-alkoxymethyl methacrylamide
- the reservoir matrices may be a polymeric matrix structure formed by blending the desired agent, drug, electrolyte, or other component(s), with an inert polymer by such processes as melt blending, solvent casting, or extrusion.
- the donor reservoir contains a agent to be delivered
- the counter reservoir contains an electrolyte, eg, a water soluble biocompatible salt, such as sodium chloride.
- the reservoirs may also contain other conventional materials such as dyes, pigments, inert fillers, and the like.
- This invention has utility in connection with the delivery of agents within the broad class deliverable through body surfaces, including skin, mucosa, and nails.
- drug and “agent” are used interchangeably herein and are intended to have their broadest inte ⁇ retation as any substance which is delivered to a living organism to produce a desired, usually beneficial, effect, in general, this includes therapeutic agents in all of the major therapeutic areas including, but not limited to, anti-infectives such as antibiotics and antiviral agents, analgesics including fentanyl, sufentanil, bupreno ⁇ hine and analgesic combinations, anesthetics, anorexics, antiarthritics, antiasthmatic agents such as terbutaline, anticonvulsants, antidepressants, antidiabetic agents, antidiarrheals, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness preparations such as scopolamine and ondansetron, antinauseants, antine
- the invention is also useful in the controlled delivery of peptides, polypeptides, proteins and other macromolecules.
- macromolecular substances typically have a molecular weight of at least about 300 daltons, s and more typically a molecular weight in the range of about 300 to 40,000 daltons.
- the present invention has particular utility in delivering drugs whose delivery rate is dependent upon the physical activity of a patient.
- drugs and the corresponding patient motion or activity include the following: delivery of theophylline or epinephrine for the treatment of apnea; delivery of an antitussive such as dextromethorphan for the treatment of coughing; delivery of an anticonvulsant for the treatment of an epileptic seizure; delivery of insulin based upon the level of patient activity (eg, lower insulin delivery rate for more vigorous levels of patient activity); delivery of antiparkinson agent in response to patient shaking; delivery of antispasmodics such as diazepam for treatment of muscle spasms; and delivery of an antiemetic such as scopolamine or meclizine, in response to motion, for the treatment of motion sickness.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Valve Device For Special Equipments (AREA)
- Refuse Collection And Transfer (AREA)
Abstract
Description
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94919291A EP0700309B1 (en) | 1993-05-28 | 1994-05-27 | Electrotransport agent delivery device |
| DE69401938T DE69401938T2 (en) | 1993-05-28 | 1994-05-27 | DEVICE FOR ELECTRIC TRANSFER DELIVERY OF ACTIVE SUBSTANCE |
| AU70484/94A AU7048494A (en) | 1993-05-28 | 1994-05-27 | Electrotransport agent delivery device |
| JP50101695A JP3504269B2 (en) | 1993-05-28 | 1994-05-27 | Electrically driven agent delivery device |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/069,270 US5445609A (en) | 1993-05-28 | 1993-05-28 | Electrotransport agent delivery device having a disposable component and a removable liner |
| US069,270 | 1993-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1994027671A1 true WO1994027671A1 (en) | 1994-12-08 |
Family
ID=22087843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1994/006070 WO1994027671A1 (en) | 1993-05-28 | 1994-05-27 | Electrotransport agent delivery device |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5445609A (en) |
| EP (1) | EP0700309B1 (en) |
| JP (1) | JP3504269B2 (en) |
| AT (1) | ATE149363T1 (en) |
| AU (1) | AU7048494A (en) |
| DE (1) | DE69401938T2 (en) |
| WO (1) | WO1994027671A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6148232A (en) * | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| US6597946B2 (en) | 1998-11-09 | 2003-07-22 | Transpharma Ltd. | Electronic card for transdermal drug delivery and analyte extraction |
| US6611706B2 (en) | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
| US6708060B1 (en) | 1998-11-09 | 2004-03-16 | Transpharma Ltd. | Handheld apparatus and method for transdermal drug delivery and analyte extraction |
| JP2008100096A (en) * | 1995-05-15 | 2008-05-01 | Alza Corp | Electrotransport device having reuseable controller |
| US8337493B2 (en) | 2002-04-19 | 2012-12-25 | Syneron Medical Ltd | Handheld transdermal drug delivery and analyte extraction |
| US9504826B2 (en) | 2009-02-18 | 2016-11-29 | Syneron Medical Ltd | Skin treatment apparatus for personal use and method for using same |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5749847A (en) * | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
| FR2709670B1 (en) * | 1993-09-10 | 1995-10-20 | Asulab Sa | Device in three modules for transdermal administration of drugs by electrophoresis or iontophoresis. |
| AU681761B2 (en) * | 1994-02-15 | 1997-09-04 | Biosearch Italia S.P.A. | Central venous catheters loaded with antibiotics of the ramoplanin group preventing development of catheter related infections |
| US5983131A (en) * | 1995-08-11 | 1999-11-09 | Massachusetts Institute Of Technology | Apparatus and method for electroporation of tissue |
| US8321013B2 (en) | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
| JP4175662B2 (en) | 1996-01-08 | 2008-11-05 | インパルス ダイナミクス エヌ.ヴイ. | Electric muscle control device |
| US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
| US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
| US7167748B2 (en) | 1996-01-08 | 2007-01-23 | Impulse Dynamics Nv | Electrical muscle controller |
| US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
| USD384745S (en) * | 1996-01-23 | 1997-10-07 | Alza Corporation | Electrotransport drug delivery system |
| AU3404197A (en) * | 1996-06-19 | 1998-01-07 | Becton Dickinson & Company | Iontophoretic delivery of cell adhesion inhibitors |
| US5857993A (en) * | 1996-07-12 | 1999-01-12 | Empi, Inc. | Process of making an iontophoresis electrode |
| US5941843A (en) * | 1996-07-12 | 1999-08-24 | Empi, Inc. | Iontophoresis electrode |
| US5871461A (en) * | 1996-07-12 | 1999-02-16 | Empi, Inc. | Method of making an iontophoresis electrode |
| US5911223A (en) * | 1996-08-09 | 1999-06-15 | Massachusetts Institute Of Technology | Introduction of modifying agents into skin by electroporation |
| US7840264B1 (en) | 1996-08-19 | 2010-11-23 | Mr3 Medical, Llc | System and method for breaking reentry circuits by cooling cardiac tissue |
| US7908003B1 (en) | 1996-08-19 | 2011-03-15 | Mr3 Medical Llc | System and method for treating ischemia by improving cardiac efficiency |
| US5797867A (en) * | 1996-09-27 | 1998-08-25 | Becton Dickinson And Company | Iontophoretic drug delivery system, including method for activating same for attachment to patient |
| US5738647A (en) * | 1996-09-27 | 1998-04-14 | Becton Dickinson And Company | User activated iontophoretic device and method for activating same |
| US5947920A (en) * | 1997-03-20 | 1999-09-07 | Dermion, Inc. | Self-contained hydrating system and iontophoresis bioelectrode |
| US6085115A (en) * | 1997-05-22 | 2000-07-04 | Massachusetts Institite Of Technology | Biopotential measurement including electroporation of tissue surface |
| DE69739334D1 (en) | 1997-07-16 | 2009-05-07 | Metacure N V | Device for controlling a smooth muscle |
| US6949081B1 (en) * | 1998-08-26 | 2005-09-27 | Non-Invasive Technology, Inc. | Sensing and interactive drug delivery |
| US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
| WO2006073671A1 (en) | 2004-12-09 | 2006-07-13 | Impulse Dynamics Nv | Protein activity modification |
| US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
| US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US7171263B2 (en) * | 1999-06-04 | 2007-01-30 | Impulse Dynamics Nv | Drug delivery device |
| US7092753B2 (en) * | 1999-06-04 | 2006-08-15 | Impulse Dynamics Nv | Drug delivery device |
| US7190997B1 (en) * | 1999-06-04 | 2007-03-13 | Impulse Dynamics Nv | Drug delivery device |
| US20040039342A1 (en) | 2000-06-08 | 2004-02-26 | Jonathan Eppstein | Transdermal integrated actuator device, methods of making and using same |
| US7030097B1 (en) * | 1999-07-14 | 2006-04-18 | Cornell Research Foundation, Inc. | Controlled nucleic acid delivery systems |
| EP2319577B1 (en) * | 2001-11-07 | 2017-03-15 | Syneron Medical Ltd. | Integrated transdermal drug delivery system |
| US9918665B2 (en) | 2002-03-11 | 2018-03-20 | Nitto Denko Corporation | Transdermal porator and patch system and method for using same |
| US8116860B2 (en) | 2002-03-11 | 2012-02-14 | Altea Therapeutics Corporation | Transdermal porator and patch system and method for using same |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | Transdermal delivery system for water insoluble drugs |
| IL152573A (en) * | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | Transdermal delivery system for anti-emetic medication |
| US7662404B2 (en) * | 2002-10-31 | 2010-02-16 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
| IL152574A (en) | 2002-10-31 | 2009-09-22 | Transpharma Medical Ltd | Transdermal delivery system for dried particulate or lyophilized medications |
| US8133505B2 (en) * | 2002-10-31 | 2012-03-13 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| US7383084B2 (en) * | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| US6745071B1 (en) * | 2003-02-21 | 2004-06-01 | Birch Point Medical, Inc. | Iontophoretic drug delivery system |
| US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
| JP2006519663A (en) | 2003-03-10 | 2006-08-31 | インパルス ダイナミックス エヌヴイ | Apparatus and method for delivering electrical signals for regulating gene expression in heart tissue |
| US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
| US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
| US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
| US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
| EP1773444B1 (en) * | 2004-06-10 | 2017-09-20 | 3M Innovative Properties Company | Patch application device and kit |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| WO2006097934A2 (en) | 2005-03-18 | 2006-09-21 | Metacure Limited | Pancreas lead |
| JP2008543359A (en) * | 2005-06-10 | 2008-12-04 | トランスファーマ メディカル,リミティド | Patch for transdermal medication |
| WO2008006219A1 (en) * | 2006-07-13 | 2008-01-17 | Cardiac Bio-Systems Inc. | Bio-electrode possessing a hydrophilic skin-contacting layer and an electrolyte substance |
| EP3210646B1 (en) * | 2007-01-22 | 2023-04-19 | PassPort Technologies, Inc. | Transdermal permeant delivery system |
| US20080234627A1 (en) * | 2007-03-22 | 2008-09-25 | Wanda Dent | Pivotally engaged multiple part electrotransport drug delivery device |
| US8197844B2 (en) | 2007-06-08 | 2012-06-12 | Activatek, Inc. | Active electrode for transdermal medicament administration |
| WO2009003173A1 (en) | 2007-06-27 | 2008-12-31 | The General Hospital Corporation | Method and apparatus for optical inhibition of photodymanic therapy |
| US20090043244A1 (en) * | 2007-08-08 | 2009-02-12 | Inan Omer T | Electrotransport Drug Delivery Device Adaptable to Skin Resistance Change |
| WO2009047774A2 (en) * | 2007-10-09 | 2009-04-16 | Transpharma Ltd. | Magnetic patch coupling |
| US8281675B2 (en) * | 2007-10-17 | 2012-10-09 | Syneron Medical Ltd | Dissolution rate verification |
| EP2211918B1 (en) * | 2007-10-29 | 2017-10-18 | Syneron Medical Ltd. | Vertical patch drying |
| JP2011505899A (en) | 2007-12-05 | 2011-03-03 | シネロン メディカル リミテッド | Disposable electromagnetic energy applicator and method of using the same |
| US8862223B2 (en) | 2008-01-18 | 2014-10-14 | Activatek, Inc. | Active transdermal medicament patch and circuit board for same |
| USD588274S1 (en) | 2008-02-12 | 2009-03-10 | Alza Corporation | Skin-adhering drug delivery patch |
| US20090312689A1 (en) * | 2008-06-05 | 2009-12-17 | Alza Corporation | Adjustable Current Electrotransport Fentanyl Delivery Device |
| US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
| EP2643048A1 (en) | 2010-11-23 | 2013-10-02 | Nupathe Inc. | User-activated self-contained co-packaged iontophoretic drug delivery system |
| US8428709B1 (en) | 2012-06-11 | 2013-04-23 | Incline Therapeutics, Inc. | Current control for electrotransport drug delivery |
| US8428708B1 (en) | 2012-05-21 | 2013-04-23 | Incline Therapeutics, Inc. | Self-test for analgesic product |
| US8301238B2 (en) | 2011-03-31 | 2012-10-30 | Incline Therapeutics, Inc. | Two-part electrotransport device |
| EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE |
| USD699855S1 (en) | 2012-11-12 | 2014-02-18 | Incline Therapeutics, Inc. | Iontophoretic drug delivery device |
| US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
| WO2016123406A1 (en) | 2015-01-28 | 2016-08-04 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| EP3267875A4 (en) | 2015-03-12 | 2018-12-05 | Chrono Therapeutics Inc. | Craving input and support system |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| US11850045B2 (en) | 2018-05-04 | 2023-12-26 | Dexcom, Inc. | Systems and methods relating to an analyte sensor system having a battery located within a disposable base |
| CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| JP2022507660A (en) | 2018-11-16 | 2022-01-18 | モーニングサイド ベンチャー インベストメンツ リミテッド | Temperature-controlled transdermal drug delivery system |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0293893A2 (en) * | 1987-06-05 | 1988-12-07 | Drug Delivery Systems Inc. | Disposable and/or replenishable drug applicators and methods of manufacturing same |
| US5037381A (en) * | 1990-07-27 | 1991-08-06 | Bock C Randolph | Electrically assisted transdermal transport device and method for renewing the device |
| WO1992004938A1 (en) * | 1990-09-25 | 1992-04-02 | Rutgers, The State University Of New Jersey | Iontotherapeutic devices, reservoir electrode devices therefor, process and unit dose |
| EP0498353A2 (en) * | 1991-02-08 | 1992-08-12 | Becton, Dickinson and Company | Device and method for renewing electrodes during iontophoresis |
| EP0513879A2 (en) * | 1984-10-12 | 1992-11-19 | Drug Delivery Systems Inc. | Transdermal drug applicator |
| EP0543241A1 (en) * | 1986-03-14 | 1993-05-26 | Drug Delivery Systems Inc. | Transdermal drug applicator and electrodes therefor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4883457A (en) * | 1983-08-18 | 1989-11-28 | Drug Delivery Systems Inc. | Disposable and/or replenishable transdermal drug applicators and methods of manufacturing same |
| US5135479A (en) * | 1983-08-18 | 1992-08-04 | Drug Delivery Systems, Inc. | Programmable control and mounting system for transdermal drug applicator |
| US4627429A (en) * | 1986-02-28 | 1986-12-09 | American Home Products Corporation | Storage-stable transdermal adhesive patch |
| US4725263A (en) * | 1986-07-31 | 1988-02-16 | Medtronic, Inc. | Programmable constant current source transdermal drug delivery system |
| US4942883A (en) * | 1987-09-29 | 1990-07-24 | Newman Martin H | Drug delivery device |
| IL86076A (en) * | 1988-04-14 | 1992-12-01 | Inventor S Funding Corp Ltd | Transdermal drug delivery device |
| DE3903794A1 (en) * | 1989-02-09 | 1990-08-16 | Lohmann Therapie Syst Lts | THERAPEUTIC SYSTEM FOR THE TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE SUBSTANCES AND ITS USE |
| WO1991015261A1 (en) * | 1990-03-30 | 1991-10-17 | Medtronic, Inc. | Activity controlled electrotransport drug delivery device |
-
1993
- 1993-05-28 US US08/069,270 patent/US5445609A/en not_active Expired - Lifetime
-
1994
- 1994-05-27 AT AT94919291T patent/ATE149363T1/en not_active IP Right Cessation
- 1994-05-27 JP JP50101695A patent/JP3504269B2/en not_active Expired - Fee Related
- 1994-05-27 EP EP94919291A patent/EP0700309B1/en not_active Expired - Lifetime
- 1994-05-27 WO PCT/US1994/006070 patent/WO1994027671A1/en active IP Right Grant
- 1994-05-27 DE DE69401938T patent/DE69401938T2/en not_active Expired - Lifetime
- 1994-05-27 AU AU70484/94A patent/AU7048494A/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0513879A2 (en) * | 1984-10-12 | 1992-11-19 | Drug Delivery Systems Inc. | Transdermal drug applicator |
| EP0543241A1 (en) * | 1986-03-14 | 1993-05-26 | Drug Delivery Systems Inc. | Transdermal drug applicator and electrodes therefor |
| EP0293893A2 (en) * | 1987-06-05 | 1988-12-07 | Drug Delivery Systems Inc. | Disposable and/or replenishable drug applicators and methods of manufacturing same |
| US4865582A (en) * | 1987-06-05 | 1989-09-12 | Drug Delivery Systems Inc. | Disposable transdermal drug applicators |
| US5037381A (en) * | 1990-07-27 | 1991-08-06 | Bock C Randolph | Electrically assisted transdermal transport device and method for renewing the device |
| WO1992004938A1 (en) * | 1990-09-25 | 1992-04-02 | Rutgers, The State University Of New Jersey | Iontotherapeutic devices, reservoir electrode devices therefor, process and unit dose |
| EP0498353A2 (en) * | 1991-02-08 | 1992-08-12 | Becton, Dickinson and Company | Device and method for renewing electrodes during iontophoresis |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008100096A (en) * | 1995-05-15 | 2008-05-01 | Alza Corp | Electrotransport device having reuseable controller |
| JP2009039557A (en) * | 1995-05-15 | 2009-02-26 | Alza Corp | Electrotransport device having reusable controller |
| US6148232A (en) * | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| US6597946B2 (en) | 1998-11-09 | 2003-07-22 | Transpharma Ltd. | Electronic card for transdermal drug delivery and analyte extraction |
| US6611706B2 (en) | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
| US6615079B1 (en) | 1998-11-09 | 2003-09-02 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| US6708060B1 (en) | 1998-11-09 | 2004-03-16 | Transpharma Ltd. | Handheld apparatus and method for transdermal drug delivery and analyte extraction |
| US6711435B2 (en) | 1998-11-09 | 2004-03-23 | Transpharma Ltd. | Transdermal drug delivery and analyte extraction |
| US7164942B2 (en) | 1998-11-09 | 2007-01-16 | Transpharma Medical Ltd. | Handheld apparatus and method for transdermal drug delivery and analyte extraction |
| US8337493B2 (en) | 2002-04-19 | 2012-12-25 | Syneron Medical Ltd | Handheld transdermal drug delivery and analyte extraction |
| US9504826B2 (en) | 2009-02-18 | 2016-11-29 | Syneron Medical Ltd | Skin treatment apparatus for personal use and method for using same |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH09500292A (en) | 1997-01-14 |
| DE69401938D1 (en) | 1997-04-10 |
| ATE149363T1 (en) | 1997-03-15 |
| EP0700309A1 (en) | 1996-03-13 |
| DE69401938T2 (en) | 1997-10-09 |
| EP0700309B1 (en) | 1997-03-05 |
| AU7048494A (en) | 1994-12-20 |
| JP3504269B2 (en) | 2004-03-08 |
| US5445609A (en) | 1995-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0700309B1 (en) | Electrotransport agent delivery device | |
| US6169920B1 (en) | Iontophoretic drug delivery apparatus | |
| EP0522011B1 (en) | Iontophoretic delivery device | |
| US5298017A (en) | Layered electrotransport drug delivery system | |
| US5162043A (en) | Iontophoretic delivery device | |
| EP0643599B1 (en) | Iontophoretic delivery device | |
| CA2181742C (en) | Reduction of skin irritation during electrotransport delivery | |
| US5919155A (en) | Electrotransport system having flexible connector means | |
| US6163720A (en) | Layered rate controlling membranes for use in an electrotransport device | |
| CA2090313A1 (en) | Iontophoretic delivery device and method of hydrating same | |
| EP1455893B1 (en) | Electrotransport device having an integrally molded reservoir housing | |
| CA2042994C (en) | Iontophoretic delivery device | |
| CA2205010C (en) | Electrotransport device having reusable controller power saver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1994919291 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1994919291 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1994919291 Country of ref document: EP |